Literature DB >> 11471765

Therapy in neuromuscular disease.

D S Younger1, N Raksadawan.   

Abstract

The therapy of myasthenia gravis and inflammatory myopathy are discussed in detail in this article. The discussion of these two disorders illustrates the extraordinary progress that has been achieved in the therapy of neuromuscular disease.

Entities:  

Mesh：

Year:  2001        PMID： 11471765     DOI： 10.1016/s0733-8619(05)70013-x

Source DB:  PubMed          Journal:  Neurol Clin        ISSN： 0733-8619            Impact factor:   3.806


  4 in total

1.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

2.  An Update on Myasthenic Crisis.

Authors:  Shafiuddin Ahmed; Jawad F Kirmani; Nazli Janjua; Ammar Alkawi; Ismail Khatri; Abutaher M Yahia; Nizar Souyah; Adnan I Qureshi
Journal:  Curr Treat Options Neurol       Date:  2005-03       Impact factor: 3.598

3.  Myasthenic Crisis.

Authors:  Jawad F. Kirmani; Abutaher M. Yahia; Adnan I. Qureshi
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

4.  Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis.

Authors:  Laura Díez-Porras; Christian Homedes; Maria Antonia Alberti; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.